Analysis of the Moscow Region registry of acromegalia patients
Yu.G. Pokramovich, A.V. Dreval

Moscow Regional Scientific Research Clinical Institute named after M.F. Vladimirskiy

Acromegalia is a rare neuroendocrine disease caused by a chronic hyperproduction of somatotrophic hormone (STH) in individuals with complete physiological growth. In 2005 the Moscow region registry of patients with acromegalia was created to carry out regular monitoring and to optimize treatment.
Aim: to conduct a comparative analysis of the data of the registry of patients with acromegalia in 2007 and 2017.
Patients and methods: the analysis of 304 patients (237 women, 67 men) included in the Moscow regional registry as of December 2017 is presented. Among them: 32 patients with newly diagnosed acromegalia, 202 patients receiving somatostatin analogues (SSA), 70 patients after surgical treatment of the adenoma of the pituitary. Instrumental and laboratory examinations of patients were carried out in the Moscow Regional Scientific Research Clinical Institute named after M.F. Vladimirskiy.
Results and discussion: the previous analysis was carried out in 2007, at that time 70 patients were registered in it (23% of the current value). The analysis of clinical manifestations of acromegalia revealed no significant differences between 2007 and 2017 (p> 0,05). Most of the patients had complaints on sweating, swelling, headache and muscle weakness, which occurred more often in women, then in men. Examination of the patients for the late complications revealed no statistically significant differences in the pathology of the cardiovascular system, the gastrointestinal tract, the thyroid gland. During the treatment of patients with Octreotide-Depot, the STH baseline decreased fr om 7,0 ng / ml to 2,5 ng / ml (p <0,05), and the median exceeding the upper lim it of normal IGF-1 decreased from 265,6% to 115,2% (p <0,05).
Conclusion: keeping a registry of patients with acromegalia allows to track the course of the desease, determine the tactics and strategy of treatment, and evaluate the effectiveness of the therapy in dynamics.

Key words: registry, acromegalia, somatotrophic hormone, IGF-1, somatostatin analogues, Moscow region, pituitary.
For citation: Pokramovich Yu.G., Dreval A.V. Analysis of the Moscow Region registry of acromegalia patients // RMJ. 2018. № 1 (I). P. 17–22.